Human Chorionic Gonadotropin (hCG) Priming Prior to Controlled Ovarian Hyperstimulation (COH) in Poor Responder In Vitro Fertilization (IVF) Patients
Phase 4
Completed
- Conditions
- Ovarian Response
- Interventions
- Biological: human chorionic gonadotropinBiological: placebo
- Registration Number
- NCT00870025
- Lead Sponsor
- IVI Madrid
- Brief Summary
There is a decline in androgen concentration with ovarian aging. Also, ovarian response to COH in IVF cycles diminishes with ovarian aging. Recent evidence suggest that testosterone or DHEA may improve ovarian response in poor prognosis patients by increasing intraovarian androgen concentration. A physiological way to induce androgen synthesis within the ovary is to stimulate theca cells androgen production by hCG stimulation. By doing this in the previous cycle we might expect a better response to COH.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
- previous IVF cycle with 5 or less mature follicles or 5 or less oocyte retrieved
Exclusion Criteria
- 42 years or older
- BMI <18 or >30
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description hCG placebo 200 IU rec hCG s.c./5 days, 4 doses prior to onset of COH hCG human chorionic gonadotropin 200 IU rec hCG s.c./5 days, 4 doses prior to onset of COH placebo placebo similar injection at same time points with similar diluent but no hCG
- Primary Outcome Measures
Name Time Method pregnancy rate 2 weeks after intervention
- Secondary Outcome Measures
Name Time Method number of oocytes retrieved 2 weeks after intervention
Trial Locations
- Locations (1)
IVI-Madrid
🇪🇸Madrid, Spain